Holen Sie sich die Stockscreener-App
3.8039
3.17%
0.1239
Schlusskurs vom Vortag:
$3.68
Offen:
$3.78
24-Stunden-Volumen:
218.21K
Relative Volume:
0.67
Marktkapitalisierung:
$205.22M
Einnahmen:
$77.36M
Nettoeinkommen (Verlust:
$-38.43M
KGV:
-5.1349
EPS:
-0.7408
Netto-Cashflow:
$-29.92M
1W Leistung:
-1.39%
1M Leistung:
-26.42%
6M Leistung:
+10.37%
1J Leistung:
+58.19%
1-Tages-Spanne:
$3.66
$4.04
1-Wochen-Bereich:
$3.63
$4.11
52-Wochen-Spanne:
$2.03
$9.2362
Sight Sciences Inc Stock (SGHT) Company Profile
Firmenname
Sight Sciences Inc
Sektor
Branche
Telefon
(415) 889-0550
Adresse
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
3.80 | 198.74M | 77.36M | -38.43M | -29.92M | -0.7408 |
ABT
Abbott Laboratories
|
102.60 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.25 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.75 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.40 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.09 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-08-08 | Hochstufung | Lake Street | Hold → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-11-04 | Herabstufung | Lake Street | Buy → Hold |
| 2024-08-21 | Eingeleitet | Lake Street | Buy |
| 2023-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-09-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-08-24 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-04 | Eingeleitet | Needham | Hold |
| 2022-07-26 | Eingeleitet | Stifel | Hold |
| 2022-02-03 | Eingeleitet | William Blair | Outperform |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Sight Sciences Inc Aktie (SGHT) Neueste Nachrichten
Sight Sciences wins $34M in Alcon patent case, ongoing royalty - Investing.com Australia
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th - Yahoo! Finance Canada
Del. Judge Upholds $34M Verdict In Glaucoma Patent Feud - Law360
Published on: 2026-03-31 02:42:17 - baoquankhu1.vn
Sight Sciences Wins $34 Million Patent Infringement Case Against Alcon, Secures Ongoing Royalties Through 2028 - Minichart
Sight Sciences U.S. district court issued order on post-trial motions in patent infringement case against Alcon originally filed on Sep 16, 2021 - marketscreener.com
Sight Sciences U.S. District Court Issued Order On Post-Trial Motions In Patent Infringement Case Against Alcon Originally Filed On Sep 16, 2021 - TradingView
Sight Sciences Wins Infringement Lawsuit Against Alcon - National Today
Sight Sciences Wins Key Patent Ruling in Glaucoma Case - TipRanks
Sight Sciences (NASDAQ: SGHT) awarded $34M plus 10% Hydrus royalties - Stock Titan
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent - marketscreener.com
Court keeps $34 million award, 10% royalties in eye-stent patent fight - Stock Titan
Growth Value: Is Sight Sciences Inc on track to beat earnings2026 Movers & Fast Gain Stock Trading Tips - baoquankhu1.vn
Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Aug Ideas: Is Sight Sciences Inc in a consolidation phase2026 Highlights & High Accuracy Investment Signals - baoquankhu1.vn
Sight Sciences Inc stock faces pressure amid weak Q4 guidance and slowing growth in eye care devices - AD HOC NEWS
Citigroup maintains Sight Sciences (SGHT) neutral recommendation - MSN
Sight Sciences outlines $82M–$88M 2026 revenue target while expanding interventional dry eye strategy - MSN
Can Sight Sciences Inc weather a recession2026 Technical Overview & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Earnings call transcript: Sight Sciences beats Q4 2025 forecasts, stock rises - Investing.com Nigeria
Prosight Management LP Sells 431,746 Shares of Sight Sciences, Inc. $SGHT - MarketBeat
Morgan Stanley Sticks to Its Hold Rating for Sight Sciences (SGHT) - The Globe and Mail
Sight Sciences (SGHT) Q4 2025 Earnings Transcript - AOL.com
Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2025 earnings call transcript - MSN
Sight Sciences Earnings Call Highlights Disciplined Growth - TipRanks
Stock Report: Can Sight Sciences Inc weather a recession2025 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Sight Sciences, Inc. (SGHT) reports Q4 loss, beats revenue estimates - MSN
S P Trends: Will Sight Sciences Inc outperform tech stocks2025 Bull vs Bear & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - WFXG
Sight Sciences (NASDAQ:SGHT) Price Target Cut to $11.00 by Analysts at UBS Group - MarketBeat
Sight Sciences (NASDAQ:SGHT) Price Target Lowered to $6.50 at Citigroup - MarketBeat
Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2025 Earnings Call Transcript - Insider Monkey
Sight Sciences (SGHT) reports Q4 earnings: What key metrics have to say - MSN
Sight Sciences Reports Preliminary Fourth Quarter 2025 Revenue Growth, Provides 2026 Outlook - VisionMonday.com
William Blair Maintains Outperform on SGHT Sight Sciences, Inc. March 2026 - Meyka
Sight Sciences (SGHT) EPS Loss Narrows Again And Tests Bearish Profitability Narratives - simplywall.st
William Blair reiterates Sight Sciences stock rating on expense control - Investing.com Nigeria
William Blair reiterates Sight Sciences stock rating on expense control By Investing.com - Investing.com India
Sight Sciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Sight Sciences Q4 Net Loss Narrows; Expects 6-14% Revenue Growth In FY26 - Nasdaq
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance - The Manila Times
Sight Sciences sees FY26 revenue $82M-$88M, consensus $86.11M - TipRanks
Sight Sciences Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Sight Sciences beats Q4 2025 forecasts, stock rises By Investing.com - Investing.com South Africa
Sight Sciences Q4 Earnings Call Highlights - MarketBeat
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates - Bitget
Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Sight Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sight Sciences reports Q4 EPS (8c), consensus (14c) - TipRanks
Sight Sciences Q4 Loss Narrows, Revenue Rises - marketscreener.com
Sight Sciences earnings beat by $0.07, revenue topped estimates - Investing.com Canada
Finanzdaten der Sight Sciences Inc-Aktie (SGHT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sight Sciences Inc-Aktie (SGHT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Badawi David | Chief Technology Officer |
Jan 16 '26 |
Sale |
6.62 |
4,836 |
32,014 |
1,912,273 |
| Rodberg James | Chief Financial Officer |
Jan 16 '26 |
Sale |
6.62 |
2,616 |
17,318 |
151,230 |
| Badawi Paul | President and CEO |
Jan 16 '26 |
Sale |
6.62 |
22,362 |
148,036 |
6,025,840 |
| HAYDEN JEREMY B. | Chief Legal Officer |
Jan 16 '26 |
Sale |
6.62 |
6,308 |
41,759 |
267,611 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):